Akebia Therapeutics, Inc.

Akebia Therapeutics is a fully integrated biopharmaceutical company focused on developing and commercializing therapeutics for kidney disease and related conditions. Its primary commercial products are Vafseo (vadadustat), an oral hypoxia-inducible factor medicine for anemia associated with chronic kidney disease in adult dialysis patients, and Auryxia (ferric citrate), an oral treatment used for serum phosphorus control in dialysis-dependent chronic kidney disease and iron deficiency anemia in non-dialysis chronic kidney disease. The company's development pipeline includes mid-stage candidates such as praliciguat for focal segmental glomerulosclerosis and AKB-097 for complement-mediated kidney diseases, alongside early-stage programs exploring acute kidney injury, lung injury, and pediatric retinal disease. Its customers and target end-users encompass dialysis organizations, nephrologists, and adult patients undergoing kidney-related medical care.

The company operates commercially within the United States, maintaining contracts that provide prescribing access across dialysis clinic networks nationwide, and commercializes therapies internationally through regional partner collaborations across 37 countries where its lead product holds regulatory approval. The provided text contains no details regarding the location of its corporate headquarters.

Summary of the business section of Akebia Therapeutics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 194 employees.”